Massachusetts General Hospital
Jason A. Efstathiou, MD, DPhil, FASTRO, FACRO is Professor of Radiation Oncology at Harvard Medical School (HMS) and Director of the Genitourinary (GU) Division in the Department of Radiation Oncology and Clinical Co-Director of The Claire and John Bertucci Center for GU Cancers at the Massachusetts General Hospital. He is an internationally recognized leader in the field of GU malignancies and Radiation Oncology. His research has informed clinical guidelines and made novel contributions to organ preservation therapy for bladder cancer, technology assessment of proton beam therapy for prostate cancer, as well as global oncology outreach efforts. He is the recipient of significant grant funding and serves as the Principal Investigator or Co-Chair of multiple multi-center, NCI-sponsored, randomized trials in bladder and prostate cancer. Dr. Efstathiou holds multiple leadership and Board positions within professional societies (ASTRO, ASCO, ABR, ACRO, ROI), patient advocacy organizations (BCAN, MPCC), within the NCI where he has served as Co-Chair of the Bladder Cancer Task Force, and within NRG Oncology where he is the Vice-Chair of the GU Steering Committee and Bladder Lead. This year, he serves as the Chair of the Genitourinary Cancers Symposium (GU ASCO) for 2021-2022. In addition, he has a strong proven track record in teaching and mentorship and was recently awarded the A. Clifford Barger Excellence in Mentoring Award from HMS. Dr. Efstathiou holds a B.S. from Yale University, M.D. from HMS, D.Phil. from the University of Oxford, and completed his residency training in the Harvard Radiation Oncology Program.
Astra Zeneca (Individual(s) Involved: Self; Clinical Condition: Oncology): Consultant; Bayer Healthcare (Individual(s) Involved: Self; Clinical Condition: Prostate cancer): Advisory Board; Blue Earth Diagnostics (Individual(s) Involved: Self; Clinical Condition: Prostate cancer): Consultant; Boston Scientific (Individual(s) Involved: Self; Clinical Condition: Prostate cancer): Consultant; Janssen (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board; Merck (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board; Myovant Biosciences (Individual(s) Involved: Self; Clinical Condition: Prostate cancer): Advisory Board; Roivant (Individual(s) Involved: Self; Clinical Condition: Prostate cancer): Advisory Board
Wednesday, March 9, 2022
3:35 PM – 4:25 PM
Thursday, March 10, 2022
8:45 AM – 10:05 AM
Thursday, March 10, 2022
9:10 AM – 9:30 AM
Thursday, March 10, 2022
9:50 AM – 10:30 AM